JP2017536092A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536092A5 JP2017536092A5 JP2017517791A JP2017517791A JP2017536092A5 JP 2017536092 A5 JP2017536092 A5 JP 2017536092A5 JP 2017517791 A JP2017517791 A JP 2017517791A JP 2017517791 A JP2017517791 A JP 2017517791A JP 2017536092 A5 JP2017536092 A5 JP 2017536092A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- hepatitis
- nucleic acid
- composition
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002245 particle Substances 0.000 claims description 116
- 239000000203 mixture Substances 0.000 claims description 90
- 241000700721 Hepatitis B virus Species 0.000 claims description 48
- 241000124008 Mammalia Species 0.000 claims description 42
- 239000008194 pharmaceutical composition Substances 0.000 claims description 40
- 108020004459 Small interfering RNA Proteins 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 34
- 208000029570 hepatitis D virus infection Diseases 0.000 claims description 33
- 210000004027 cell Anatomy 0.000 claims description 32
- 208000002672 hepatitis B Diseases 0.000 claims description 32
- 230000014509 gene expression Effects 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 150000002632 lipids Chemical class 0.000 claims description 21
- 230000030279 gene silencing Effects 0.000 claims description 17
- 208000024891 symptom Diseases 0.000 claims description 17
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 16
- 150000003904 phospholipids Chemical class 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- -1 cationic lipid Chemical class 0.000 claims description 12
- 208000037262 Hepatitis delta Diseases 0.000 claims description 11
- 241000724709 Hepatitis delta virus Species 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 235000012000 cholesterol Nutrition 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 208000019423 liver disease Diseases 0.000 claims description 8
- 230000009885 systemic effect Effects 0.000 claims description 8
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 6
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 6
- 238000004220 aggregation Methods 0.000 claims description 6
- 230000002776 aggregation Effects 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 125000002091 cationic group Chemical group 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 231100000283 hepatitis Toxicity 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 230000010076 replication Effects 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 2
- ARJCMRWHZPDQJG-ASSJVFBPSA-N [(6z,16z)-12-[(z)-dec-4-enyl]docosa-6,16-dien-11-yl] 5-(dimethylamino)pentanoate Chemical compound CCCCC\C=C/CCCC(CCC\C=C/CCCCC)C(CCC\C=C/CCCCC)OC(=O)CCCCN(C)C ARJCMRWHZPDQJG-ASSJVFBPSA-N 0.000 claims description 2
- 229940106189 ceramide Drugs 0.000 claims description 2
- 150000001841 cholesterols Chemical class 0.000 claims description 2
- VHRYAHCCVUHIBM-NSOMFCEZSA-N n,n-dimethyl-1,2-bis[(6z,9z,12z)-octadeca-6,9,12-trienoxy]propan-1-amine Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCOC(C)C(N(C)C)OCCCCC\C=C/C\C=C/C\C=C/CCCCC VHRYAHCCVUHIBM-NSOMFCEZSA-N 0.000 claims description 2
- XVUQPECVOGMPRU-ZPPAUJSGSA-N n,n-dimethyl-1,2-bis[(9z,12z)-octadeca-9,12-dienoxy]propan-1-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCOC(C)C(N(C)C)OCCCCCCCC\C=C/C\C=C/CCCCC XVUQPECVOGMPRU-ZPPAUJSGSA-N 0.000 claims description 2
- NFQBIAXADRDUGK-KWXKLSQISA-N n,n-dimethyl-2,3-bis[(9z,12z)-octadeca-9,12-dienoxy]propan-1-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCOCC(CN(C)C)OCCCCCCCC\C=C/C\C=C/CCCCC NFQBIAXADRDUGK-KWXKLSQISA-N 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 230000029812 viral genome replication Effects 0.000 claims description 2
- 238000013160 medical therapy Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462059056P | 2014-10-02 | 2014-10-02 | |
| US62/059,056 | 2014-10-02 | ||
| US201562120149P | 2015-02-24 | 2015-02-24 | |
| US62/120,149 | 2015-02-24 | ||
| PCT/US2015/053569 WO2016054421A1 (en) | 2014-10-02 | 2015-10-01 | Compositions and methods for silencing hepatitis b virus gene expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017536092A JP2017536092A (ja) | 2017-12-07 |
| JP2017536092A5 true JP2017536092A5 (enExample) | 2018-03-15 |
Family
ID=54325078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017517791A Pending JP2017536092A (ja) | 2014-10-02 | 2015-10-01 | Ｂ型肝炎ウイルスの遺伝子発現をサイレンシングするための組成物及び方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10415037B2 (enExample) |
| EP (1) | EP3201338B1 (enExample) |
| JP (1) | JP2017536092A (enExample) |
| KR (1) | KR20170075742A (enExample) |
| CN (1) | CN107208095B (enExample) |
| AU (1) | AU2015328012A1 (enExample) |
| BR (1) | BR112017006679A2 (enExample) |
| CA (1) | CA2963271A1 (enExample) |
| CL (1) | CL2017000780A1 (enExample) |
| CO (1) | CO2017004290A2 (enExample) |
| CR (1) | CR20170174A (enExample) |
| IL (1) | IL251450A0 (enExample) |
| PH (1) | PH12017500614A1 (enExample) |
| RU (1) | RU2017114964A (enExample) |
| SG (1) | SG11201702662UA (enExample) |
| TW (2) | TW201623614A (enExample) |
| WO (1) | WO2016054421A1 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ588583A (en) | 2008-04-15 | 2012-08-31 | Protiva Biotherapeutics Inc | Novel lipid formulations for nucleic acid delivery |
| US8283333B2 (en) | 2009-07-01 | 2012-10-09 | Protiva Biotherapeutics, Inc. | Lipid formulations for nucleic acid delivery |
| PL3338765T3 (pl) | 2009-12-01 | 2019-06-28 | Translate Bio, Inc. | Pochodna steroidowa dla dostarczania mrna w ludzkich chorobach genetycznych |
| WO2012000104A1 (en) | 2010-06-30 | 2012-01-05 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
| US8853377B2 (en) | 2010-11-30 | 2014-10-07 | Shire Human Genetic Therapies, Inc. | mRNA for use in treatment of human genetic diseases |
| PT2717893T (pt) | 2011-06-08 | 2019-08-20 | Translate Bio Inc | Composições de nanopartículas lipídicas e métodos para transferência de arnm |
| WO2013185069A1 (en) | 2012-06-08 | 2013-12-12 | Shire Human Genetic Therapies, Inc. | Pulmonary delivery of mrna to non-lung target cells |
| WO2013185067A1 (en) | 2012-06-08 | 2013-12-12 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
| EP2968586B1 (en) | 2013-03-14 | 2018-07-25 | Translate Bio, Inc. | Cftr mrna compositions and related methods and uses |
| ES2981185T3 (es) | 2013-03-14 | 2024-10-07 | Translate Bio Inc | Métodos para la purificación de ARN mensajero |
| ES2882110T3 (es) | 2013-03-14 | 2021-12-01 | Translate Bio Inc | Métodos y composiciones para administrar anticuerpos codificados con ARNm |
| EP4614148A3 (en) | 2013-03-15 | 2025-12-17 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
| WO2015061467A1 (en) | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Lipid formulations for delivery of messenger rna |
| MX2016005239A (es) | 2013-10-22 | 2016-08-12 | Shire Human Genetic Therapies | Tratamiento con acido ribonucleico mensajero para la fenilcetonuria. |
| US11224642B2 (en) | 2013-10-22 | 2022-01-18 | Translate Bio, Inc. | MRNA therapy for argininosuccinate synthetase deficiency |
| CA2928040A1 (en) | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Cns delivery of mrna and uses thereof |
| JP6571679B2 (ja) | 2014-04-25 | 2019-09-04 | トランスレイト バイオ， インコーポレイテッド | メッセンジャーｒｎａの精製方法 |
| US10022455B2 (en) | 2014-05-30 | 2018-07-17 | Translate Bio, Inc. | Biodegradable lipids for delivery of nucleic acids |
| CA2952824C (en) | 2014-06-24 | 2023-02-21 | Shire Human Genetic Therapies, Inc. | Stereochemically enriched compositions for delivery of nucleic acids |
| CA2953265C (en) | 2014-07-02 | 2023-09-26 | Shire Human Genetic Therapies, Inc. | Encapsulation of messenger rna |
| MA56412A (fr) | 2014-12-05 | 2022-05-04 | Translate Bio Inc | Thérapie par l'arn messager pour le traitement des maladies articulaires |
| WO2016149508A1 (en) | 2015-03-19 | 2016-09-22 | Shire Human Genetic Therapies, Inc. | Mrna therapy for pompe disease |
| CA2996722A1 (en) | 2015-07-17 | 2017-01-26 | Arcturus Therapeutics, Inc. | Compositions and agents against hepatitis b virus and uses thereof |
| US20170137821A1 (en) | 2015-07-17 | 2017-05-18 | Arcturus Therapeutics, Inc. | Molecules and agents for treating hepatitis b virus |
| HK1248278A1 (zh) * | 2015-07-29 | 2018-10-12 | Arbutus Biopharma Corporation | 用於使乙型肝炎病毒基因表达沉默的组合物及方法 |
| CN108473969B9 (zh) | 2015-10-14 | 2024-08-23 | 川斯勒佰尔公司 | 用于增强生产的rna相关酶的修饰 |
| KR102369898B1 (ko) | 2016-04-08 | 2022-03-03 | 트랜슬레이트 바이오 인코포레이티드 | 다량체 코딩 핵산 및 그 용도 |
| CN109312313A (zh) | 2016-06-13 | 2019-02-05 | 川斯勒佰尔公司 | 用于治疗鸟氨酸转氨甲酰酶缺乏症的信使rna疗法 |
| CN116751200A (zh) * | 2016-11-07 | 2023-09-15 | 爱彼特生物制药公司 | 含有取代的吡啶酮的三环化合物以及使用其的方法 |
| US11351118B2 (en) | 2016-12-21 | 2022-06-07 | Arbutus Biopharma Corporation | Methods for ameliorating infusion reactions |
| AU2018224326B2 (en) | 2017-02-27 | 2024-01-04 | Translate Bio, Inc. | Novel codon-optimized CFTR mRNA |
| MX2019013752A (es) | 2017-05-16 | 2020-07-20 | Translate Bio Inc | Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones. |
| AR112166A1 (es) * | 2017-06-16 | 2019-09-25 | Arbutus Biopharma Corp | Composiciones terapéuticas y métodos para el tratamiento de hepatitis b |
| CN107291266B (zh) * | 2017-06-21 | 2018-08-31 | 腾讯科技（深圳）有限公司 | 图像显示的方法和装置 |
| WO2019051257A2 (en) * | 2017-09-11 | 2019-03-14 | Arbutus Biopharma Corporation | METHODS OF TREATING HEPATITIS B TYPE INFECTIONS |
| CN111511914B (zh) | 2017-10-16 | 2023-11-17 | 豪夫迈·罗氏有限公司 | 减少PAPD5和PAPD7 mRNA的核酸分子用于治疗乙型肝炎感染 |
| US11167043B2 (en) | 2017-12-20 | 2021-11-09 | Translate Bio, Inc. | Composition and methods for treatment of ornithine transcarbamylase deficiency |
| US11702427B2 (en) | 2018-03-12 | 2023-07-18 | Arbutus Biopharma Corporation | Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same |
| EP3775208A1 (en) | 2018-04-05 | 2021-02-17 | F. Hoffmann-La Roche AG | Use of fubp1 inhibitors for treating hepatitis b virus infection |
| EP3773584A4 (en) | 2018-04-12 | 2022-01-05 | Arbutus Biopharma Corporation | METHOD FOR PRODUCING SUBSTITUTED PYRIDINONE-CONTAINING TRICYCLIC COMPOUNDS |
| CN118421617A (zh) | 2018-08-24 | 2024-08-02 | 川斯勒佰尔公司 | 用于纯化信使rna的方法 |
| WO2020087107A1 (en) * | 2018-10-31 | 2020-05-07 | The University Of Sydney | Compositions and methods for treating viral infections |
| CN113286882A (zh) * | 2018-11-09 | 2021-08-20 | 阿布特斯生物制药公司 | 脂质纳米颗粒制剂 |
| CN113728101A (zh) * | 2018-11-09 | 2021-11-30 | 阿布特斯生物制药公司 | 脂质纳米颗粒制剂 |
| EP3883592A1 (en) | 2018-11-21 | 2021-09-29 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr |
| JP2022516449A (ja) | 2018-12-24 | 2022-02-28 | セレキシス エスエー | チャイニーズハムスター卵巣細胞における内在性レトロウイルスの特性評価および不活性化 |
| WO2021055609A1 (en) | 2019-09-20 | 2021-03-25 | Translate Bio, Inc. | Mrna encoding engineered cftr |
| CA3164931A1 (en) | 2019-12-24 | 2021-07-01 | Selexis Sa | Targeted integration in mammalian sequences enhancing gene expression |
| AR122731A1 (es) | 2020-06-26 | 2022-10-05 | Hoffmann La Roche | Oligonucleótidos mejorados para modular la expresión de fubp1 |
| RU2733361C1 (ru) * | 2020-07-14 | 2020-10-01 | Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) | Средство для ингибирования репликации вируса SARS-CoV-2, опосредованного РНК-интерференцией |
| RU2746362C9 (ru) * | 2021-03-11 | 2021-04-26 | Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) | Комбинированное лекарственное средство, обладающее противовирусным эффектом в отношении нового коронавируса SARS-CoV-2 |
| US20250236820A1 (en) * | 2022-01-17 | 2025-07-24 | Isp Investments Llc | Biodegradable microcapsules with improved storage stability, process for preparing the same and method of use thereof |
Family Cites Families (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3993754A (en) | 1974-10-09 | 1976-11-23 | The United States Of America As Represented By The United States Energy Research And Development Administration | Liposome-encapsulated actinomycin for cancer chemotherapy |
| US4086257A (en) | 1976-10-12 | 1978-04-25 | Sears Barry D | Phosphatidyl quaternary ammonium compounds |
| CH624011A5 (enExample) | 1977-08-05 | 1981-07-15 | Battelle Memorial Institute | |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4522803A (en) | 1983-02-04 | 1985-06-11 | The Liposome Company, Inc. | Stable plurilamellar vesicles, their preparation and use |
| US4588578A (en) | 1983-08-08 | 1986-05-13 | The Liposome Company, Inc. | Lipid vesicles prepared in a monophase |
| US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
| US5286634A (en) | 1989-09-28 | 1994-02-15 | Stadler Joan K | Synergistic method for host cell transformation |
| US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
| ES2105262T3 (es) | 1992-05-18 | 1997-10-16 | Minnesota Mining & Mfg | Dispositivo de suministro de farmaco a traves de las mucosas. |
| US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
| US5426039A (en) | 1993-09-08 | 1995-06-20 | Bio-Rad Laboratories, Inc. | Direct molecular cloning of primer extended DNA containing an alkane diol |
| FR2715847B1 (fr) | 1994-02-08 | 1996-04-12 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| FR2722506B1 (fr) | 1994-07-13 | 1996-08-14 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucleiques, preparation et utilisations |
| US5908635A (en) | 1994-08-05 | 1999-06-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method for the liposomal delivery of nucleic acids |
| US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| ATE219660T1 (de) | 1994-09-30 | 2002-07-15 | Inex Pharmaceuticals Corp | Mittel zum einbringen polyanionischer materialien in zellen |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5756122A (en) | 1995-06-07 | 1998-05-26 | Georgetown University | Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells |
| CA2222328C (en) | 1995-06-07 | 2012-01-10 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5705385A (en) | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| IL115199A (en) | 1995-09-07 | 2005-05-17 | Opperbas Holding Bv | Composition comprising a polynucleic acid molecule in a liposome and method using said composition |
| US6620805B1 (en) | 1996-03-14 | 2003-09-16 | Yale University | Delivery of nucleic acids by porphyrins |
| AU2911197A (en) | 1996-05-24 | 1998-01-05 | Imperial College Of Science, Technology And Medicine | Polycationic sterol derivatives as transfection agents |
| US6251433B1 (en) | 1996-08-13 | 2001-06-26 | Chiron Corporation | Polycationic polymers |
| US6126965A (en) | 1997-03-21 | 2000-10-03 | Georgetown University School Of Medicine | Liposomes containing oligonucleotides |
| US20030229040A1 (en) | 1997-03-21 | 2003-12-11 | Georgetown University | Cationic liposomal delivery system and therapeutic use thereof |
| WO1998051278A2 (en) | 1997-05-14 | 1998-11-19 | Inex Pharmaceuticals Corporation | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| WO1999001579A1 (en) | 1997-07-01 | 1999-01-14 | Isis Pharmaceuticals, Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
| US20030073640A1 (en) | 1997-07-23 | 2003-04-17 | Ribozyme Pharmaceuticals, Inc. | Novel compositions for the delivery of negatively charged molecules |
| WO1999005303A1 (en) | 1997-07-24 | 1999-02-04 | Inex Pharmaceuticals Corporation | Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method |
| JP2001510808A (ja) | 1997-07-24 | 2001-08-07 | イネックス ファーマシューティカルズ コーポレイション | 核酸触媒の供給のためのリポソーム組成物 |
| US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
| US7091192B1 (en) | 1998-07-01 | 2006-08-15 | California Institute Of Technology | Linear cyclodextrin copolymers |
| US6509323B1 (en) | 1998-07-01 | 2003-01-21 | California Institute Of Technology | Linear cyclodextrin copolymers |
| WO2000003683A2 (en) | 1998-07-20 | 2000-01-27 | Inex Pharmaceuticals Corporation | Liposomal encapsulated nucleic acid-complexes |
| CA2362550C (en) | 1999-02-22 | 2010-05-11 | Georgetown University | Antibody fragment-targeted immunoliposomes for systemic gene delivery |
| US6852334B1 (en) | 1999-04-20 | 2005-02-08 | The University Of British Columbia | Cationic peg-lipids and methods of use |
| EP1173600A2 (en) | 1999-04-20 | 2002-01-23 | The University Of British Columbia | Cationic peg-lipids and methods of use |
| US7112337B2 (en) | 1999-04-23 | 2006-09-26 | Alza Corporation | Liposome composition for delivery of nucleic acid |
| US7098032B2 (en) | 2001-01-02 | 2006-08-29 | Mirus Bio Corporation | Compositions and methods for drug delivery using pH sensitive molecules |
| US6200599B1 (en) | 1999-10-07 | 2001-03-13 | The Regents Of The University Of California | Ortho ester lipids |
| US20050037086A1 (en) | 1999-11-19 | 2005-02-17 | Zycos Inc., A Delaware Corporation | Continuous-flow method for preparing microparticles |
| CA2402613A1 (en) | 2000-03-29 | 2001-10-04 | Igor Gonda | Cationic liposomes |
| US7189705B2 (en) | 2000-04-20 | 2007-03-13 | The University Of British Columbia | Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers |
| EP1292285A4 (en) | 2000-06-02 | 2009-07-22 | Eisai Corp North America | SYSTEMS FOR DISPENSING BIOACTIVE AGENTS |
| US20030072794A1 (en) | 2000-06-09 | 2003-04-17 | Teni Boulikas | Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes |
| US7427394B2 (en) | 2000-10-10 | 2008-09-23 | Massachusetts Institute Of Technology | Biodegradable poly(β-amino esters) and uses thereof |
| US7053150B2 (en) | 2000-12-18 | 2006-05-30 | Nektar Therapeutics Al, Corporation | Segmented polymers and their conjugates |
| TW593427B (en) | 2000-12-18 | 2004-06-21 | Nektar Therapeutics Al Corp | Synthesis of high molecular weight non-peptidic polymer derivatives |
| TWI321054B (en) | 2000-12-19 | 2010-03-01 | California Inst Of Techn | Compositions containing inclusion complexes |
| EP1385479A4 (en) | 2001-03-26 | 2006-12-06 | Alza Corp | LIPOSOMIC COMPOSITION FOR IMPROVED INTRA-CELLULAR RELEASE OF A THERAPEUTIC AGENT |
| WO2002076427A2 (en) | 2001-03-26 | 2002-10-03 | Thomas Jefferson University | Ph sensitive liposomal drug delivery |
| US20030026831A1 (en) | 2001-04-20 | 2003-02-06 | Aparna Lakkaraju | Anionic liposomes for delivery of bioactive agents |
| AU2002256398A2 (en) | 2001-04-30 | 2002-11-11 | Targeted Genetics Corporation | Lipid-comprising drug delivery complexes and methods for their production |
| US20030077829A1 (en) | 2001-04-30 | 2003-04-24 | Protiva Biotherapeutics Inc.. | Lipid-based formulations |
| DE10127526A1 (de) | 2001-05-31 | 2002-12-12 | Novosom Ag | Verfahren zur Herstellung und Auflösung von Nano- und Mikrokapseln |
| AU2002323151A1 (en) | 2001-08-13 | 2003-03-03 | University Of Pittsburgh | Application of lipid vehicles and use for drug delivery |
| US7101995B2 (en) | 2001-08-27 | 2006-09-05 | Mirus Bio Corporation | Compositions and processes using siRNA, amphipathic compounds and polycations |
| DE10152145A1 (de) | 2001-10-19 | 2003-05-22 | Novosom Ag | Stabilisierung von Liposomen und Emulsionen |
| AU2002368202B2 (en) | 2001-11-02 | 2008-06-05 | Insert Therapeutics, Inc | Methods and compositions for therapeutic use of RNA interference |
| DE10157046A1 (de) | 2001-11-18 | 2003-06-12 | Novosom Ag | Nano- und Mikrokapseln umfassend Reaktivpolymere |
| WO2003057190A1 (en) | 2001-12-31 | 2003-07-17 | Elan Pharmaceuticals, Inc. | Efficient nucleic acid encapsulation into medium sized liposomes |
| WO2003059322A1 (en) | 2002-01-09 | 2003-07-24 | Elan Pharmaceuticals, Inc. | Efficient nucleic acid encapsulation into medium sized liposomes |
| EP1480657A4 (en) | 2002-02-01 | 2006-07-05 | Intradigm Corp | POLYMERS FOR ADMINISTERING PEPTIDES AND SMALL MOLECULES IN VIVO / I |
| DE10207177A1 (de) | 2002-02-19 | 2003-09-04 | Novosom Ag | Fakultativ kationische Lipide |
| US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
| AU2003239121A1 (en) | 2002-02-22 | 2003-09-09 | Insert Therapeutics, Inc. | Carbohydrate-modified polymers, compositions and uses related thereto |
| US7037520B2 (en) | 2002-03-22 | 2006-05-02 | Baylor College Of Medicine | Reversible masking of liposomal complexes for targeted delivery |
| WO2003083443A2 (en) | 2002-03-29 | 2003-10-09 | University Of Florida | Lipid mediated screening of drug candidates for identification of active compounds |
| ES2328031T3 (es) | 2002-05-24 | 2009-11-06 | F. Hoffmann-La Roche Ag | Composiciones para distribuir acidos nucleicos a celulas. |
| BR0311995A (pt) | 2002-06-20 | 2005-04-05 | Cytos Biotechnology Ag | Partìculas semelhantes a vìrus empacotadas para o uso como adjuvantes: método de preparação e uso |
| EP1519714B1 (en) | 2002-06-28 | 2010-10-20 | Protiva Biotherapeutics Inc. | Method and apparatus for producing liposomes |
| US7682626B2 (en) | 2003-02-07 | 2010-03-23 | Roche Madison Inc. | Polyvinylethers for delivery of polynucleotides to mammalian cells |
| SG190613A1 (en) | 2003-07-16 | 2013-06-28 | Protiva Biotherapeutics Inc | Lipid encapsulated interfering rna |
| CN1882693B (zh) | 2003-09-15 | 2012-08-15 | 普洛体维生物治疗公司 | 聚乙二醇修饰的脂质化合物及其应用 |
| ATE536418T1 (de) | 2004-06-07 | 2011-12-15 | Protiva Biotherapeutics Inc | Lipidverkapselte interferenz-rna |
| WO2005120152A2 (en) | 2004-06-07 | 2005-12-22 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
| US7883688B2 (en) | 2005-02-03 | 2011-02-08 | Agency For Science, Technology And Research | Polycationic polyrotaxanes capable of forming complexes with nucleic acids |
| WO2007086883A2 (en) | 2005-02-14 | 2007-08-02 | Sirna Therapeutics, Inc. | Cationic lipids and formulated molecular compositions containing them |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| CN103989633A (zh) | 2005-07-27 | 2014-08-20 | 普洛体维生物治疗公司 | 制造脂质体的系统和方法 |
| WO2008042973A2 (en) | 2006-10-03 | 2008-04-10 | Alnylam Pharmaceuticals, Inc. | Lipid containing formulations |
| BRPI0811170B8 (pt) | 2007-05-22 | 2021-05-25 | Arcturus Therapeutics Inc | oligonucleotídeos de rna e complexos de rna substituídos por hidroximetila |
| JP5749494B2 (ja) | 2008-01-02 | 2015-07-15 | テクミラ ファーマシューティカルズ コーポレイション | 核酸の送達のための改善された組成物および方法 |
| NZ588583A (en) | 2008-04-15 | 2012-08-31 | Protiva Biotherapeutics Inc | Novel lipid formulations for nucleic acid delivery |
| CN101603042B (zh) | 2008-06-13 | 2013-05-01 | 厦门大学 | 可用于乙型肝炎病毒感染治疗的rna干扰靶点 |
| JP5642673B2 (ja) | 2008-07-10 | 2014-12-17 | セリナ・セラピユーテイツクス・インコーポレーテツド | 不活性末端基を有するポリオキサゾリン類、保護された開始基から調製されるポリオキサゾリン類及び関連化合物 |
| JP5816556B2 (ja) | 2008-12-03 | 2015-11-18 | アークトゥラス・セラピューティクス・インコーポレイテッドＡｒｃｔｕｒｕｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 治療剤のためのｕｎａオリゴマー構造 |
| US20110071208A1 (en) | 2009-06-05 | 2011-03-24 | Protiva Biotherapeutics, Inc. | Lipid encapsulated dicer-substrate interfering rna |
| US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| US8283333B2 (en) | 2009-07-01 | 2012-10-09 | Protiva Biotherapeutics, Inc. | Lipid formulations for nucleic acid delivery |
| WO2011139710A1 (en) | 2010-04-26 | 2011-11-10 | Marina Biotech, Inc. | Nucleic acid compounds with conformationally restricted monomers and uses thereof |
| EP2606134B1 (en) * | 2010-08-17 | 2019-04-10 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| JP6165723B2 (ja) * | 2011-06-30 | 2017-07-19 | アローヘッド ファーマシューティカルズ インコーポレイテッド | Ｂ型肝炎ウイルスの遺伝子発現を阻害するための組成物および方法 |
| WO2013159109A1 (en) * | 2012-04-20 | 2013-10-24 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis b virus (hbv) expression |
-
2015
- 2015-10-01 KR KR1020177011725A patent/KR20170075742A/ko not_active Withdrawn
- 2015-10-01 JP JP2017517791A patent/JP2017536092A/ja active Pending
- 2015-10-01 AU AU2015328012A patent/AU2015328012A1/en not_active Abandoned
- 2015-10-01 CA CA2963271A patent/CA2963271A1/en not_active Abandoned
- 2015-10-01 CN CN201580062374.9A patent/CN107208095B/zh active Active
- 2015-10-01 WO PCT/US2015/053569 patent/WO2016054421A1/en not_active Ceased
- 2015-10-01 SG SG11201702662UA patent/SG11201702662UA/en unknown
- 2015-10-01 BR BR112017006679A patent/BR112017006679A2/pt not_active Application Discontinuation
- 2015-10-01 EP EP15781007.8A patent/EP3201338B1/en active Active
- 2015-10-01 US US15/515,952 patent/US10415037B2/en active Active
- 2015-10-01 CR CR20170174A patent/CR20170174A/es unknown
- 2015-10-01 RU RU2017114964A patent/RU2017114964A/ru not_active Application Discontinuation
- 2015-10-02 TW TW104132625A patent/TW201623614A/zh unknown
- 2015-10-02 TW TW107110295A patent/TW201900876A/zh unknown
-
2017
- 2017-03-29 IL IL251450A patent/IL251450A0/en unknown
- 2017-03-31 CL CL2017000780A patent/CL2017000780A1/es unknown
- 2017-04-03 PH PH12017500614A patent/PH12017500614A1/en unknown
- 2017-04-27 CO CONC2017/0004290A patent/CO2017004290A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107208095B (zh) | 用于使乙型肝炎病毒基因表达沉默的组合物和方法 | |
| JP7086870B2 (ja) | メッセンジャーｒｎａを送達するための組成物及び方法 | |
| JP5475753B2 (ja) | 核酸送達用の脂質製剤 | |
| JP5766188B2 (ja) | 固形腫瘍に治療剤を送達するための脂質製剤 | |
| JP5977394B2 (ja) | 脂質に封入された干渉ｒｎａ | |
| JP7150608B2 (ja) | 多量体コード核酸及びその使用 | |
| JP2016525146A5 (enExample) | ||
| US20180245074A1 (en) | Treating hepatitis b virus infection using crispr | |
| JP7325327B2 (ja) | インフュージョンリアクションを改善するための方法 | |
| WO2016071857A1 (en) | Compositions and methods for silencing ebola virus expression | |
| JP2014530602A5 (enExample) | ||
| BR112021008953A2 (pt) | partículas de ácido nucleico-lipídio e de ácido-lipídio, composições, métodos para introduzir um ácido nucleico em uma célula, para distribuição in vivo de um ácido nucleico, para tratar uma doença ou um distúrbio e para preparar um composto, usos de uma partícula, compostos e nanopartícula de lipídio | |
| TW201718856A (zh) | 用於使b型肝炎病毒基因表現沈默之組合物及方法 | |
| JP7843707B2 (ja) | 肝星細胞への治療薬の脂質ナノ粒子送達のためのカチオン性脂質 | |
| CN110974981A (zh) | 用于递送信使rna的组合物和方法 | |
| JP2011516094A5 (enExample) | ||
| TW202539707A (zh) | 用於治療ｂ型肝炎之治療組成物及方法 | |
| TW201919653A (zh) | 用於治療ｂ型肝炎之治療組合物及方法 | |
| JP2023518944A5 (enExample) | ||
| CN110022895A (zh) | 用于治疗乙型肝炎的治疗组合物和方法 | |
| EP4251598A2 (en) | Long-acting and long-circulating delivery vehicles | |
| US20220184113A1 (en) | RATIONALLY DESIGNED ANTIVIRAL COMPOUNDS THAT INHIBIT SARS-CoV-2 AND THEIR METHODS OF USE THEREOF | |
| EA050406B1 (ru) | Катионные липиды, содержащие кремний | |
| HK1245271B (zh) | 胺阳离子脂质及其用途 | |
| HK1234102B (en) | Compositions and methods for silencing hepatitis b virus gene expression |